Photo taken from Matthew Goetz/LinkedIn
Apr 13, 2025, 06:09
Matthew Goetz: Endocrine Therapy Omission in Estrogen Receptor–Low Early-Stage Breast Cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:
“There is great controversy regarding the benefit of endocrine therapy (ET) in estrogen receptor (ER) low (1-10%) breast cancer.
Our data published online today demonstrates that ET omission in ER low breast cancer is associated with significantly higher rates of death, especially in patients with residual disease following neoadjuvant chemotherapy (NAC) and those with higher ER (6-10%) levels. Physicians should retest the residual tumor following NAC for ER and recommend ET for ER+ tumors.”
“Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer.”
Authors: Grace M. Choong, Tanya L. Hoskin, Judy C. Boughey, James N. Ingle, Matthew P. Goetz
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 14:42
Apr 14, 2025, 14:30
Apr 14, 2025, 13:49
Apr 14, 2025, 13:47
Apr 14, 2025, 13:40
Apr 14, 2025, 13:36
Apr 14, 2025, 13:31
Apr 14, 2025, 13:19